Metabolism encompasses the biochemical processes vital for sustaining life, including growth, reproduction, damage repair, and environmental response. Disruptions in these processes can lead to various metabolic disorders, such as diabetes, obesity, thyroid disease, and lipid disorders. The rising prevalence of these conditions is straining healthcare systems globally, making the discovery of novel therapeutics crucial.
Eurofins Discovery: Leading Metabolic Disorder Drug Discovery
Eurofins Discovery’s integrated team of experts has extensive experience in all major metabolic disorders and our proven track record of helping to discover drug candidates sets us apart. Our scientists excel at:
- Designing translational approaches from target-based assays to disease-relevant primary cellular systems
- Identifying safety and efficacy properties critical for clinical success
- Providing comprehensive support at every step, from early discovery to in vivo efficacy models
By partnering with Eurofins Discovery, you gain access to innovative approaches and solutions that advance your metabolic disease programs swiftly and effectively, helping you achieve your research goals and discover your next preclinical candidate.
Key Features of Our Metabolic Disorder Solutions
In Vitro Pharmacology
- Save time with 10,000+ ready-to-use, robust assays for primary and selectivity screening for GPCRs, nuclear hormone receptors (NHRs), transporters, metabolic enzymes & more
- Accelerate project timelines with high throughput assays and services, including high content imaging
- Collaborate with our scientists to develop custom solutions in primary cells, including adipocytes, pancreatic islets, & hepatocytes
- Quickly assess multiple targets relevant to the therapeutic area by using expertly curated panels, including Insulin Release and Sensitivity panels, obesity targets (ObesityLite) panel, and metabolic dysfunction-associated steatohepatitis (MASH) panel
- Deepen your understanding using BioMAP® human primary cell systems which enable mode of action elucidation, standard of care benchmarking and toxicity assessment
In Vivo Pharmacology
- Comprehensive lipid profiling: Total cholesterol, HDL, LDL, and triglycerides (TG)
- Diabetes models: Type I and Type II
- Diet-induced obesity models
- Models of MASH with high clinical relevance, including chimeric mice with humanized liver
- Evaluate mechanism with acute models of appetite and nausea
